CellArtgen Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.74M

  • Investors
  • 6

CellArtgen General Information

Description

Developer of regenerative therapeutics designed to treat diseases by replacing tissues and organs of the human body. The company's therapeutics reflect the genetic characteristics of each tissue that makes up the actual organ, and the arrangement of cells is similar to that of a real organ, enabling healthcare professionals to potentially treat nonalcoholic steatohepatitis, Alzheimer's disease, and pulmonary fibrosis.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 332 ABC, Yonsei University Engineering Building
  • 50 Yonsei-ro, Seodaemun-gu
  • Seoul
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 332 ABC, Yonsei University Engineering Building
  • 50 Yonsei-ro, Seodaemun-gu
  • Seoul
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CellArtgen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 01-Dec-2025 $2.74M Completed Generating Revenue
3. Early Stage VC 01-May-2022 Completed Generating Revenue
2. Seed Round 07-Sep-2021 Completed Generating Revenue
1. Accelerator/Incubator 01-Sep-2021 Completed Generating Revenue
To view CellArtgen’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

CellArtgen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CellArtgen Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
iAccel (Seongnam-si) Venture Capital Minority
Moneyball Ventures Venture Capital Minority
Ray (Diagnostic Equipment) Corporation Minority
Seoul National University Technology Holdings Accelerator/Incubator Minority
Yeonsei Technology Holdings Holding Company Minority
You’re viewing 5 of 6 investors. Get the full list »

CellArtgen FAQs

  • When was CellArtgen founded?

    CellArtgen was founded in 2020.

  • Where is CellArtgen headquartered?

    CellArtgen is headquartered in Seoul, South Korea.

  • What is the size of CellArtgen?

    CellArtgen has 21 total employees.

  • What industry is CellArtgen in?

    CellArtgen’s primary industry is Biotechnology.

  • Is CellArtgen a private or public company?

    CellArtgen is a Private company.

  • What is CellArtgen’s current revenue?

    The current revenue for CellArtgen is .

  • How much funding has CellArtgen raised over time?

    CellArtgen has raised $2.74M.

  • Who are CellArtgen’s investors?

    iAccel (Seongnam-si), Moneyball Ventures, Ray (Diagnostic Equipment), Seoul National University Technology Holdings, and Yeonsei Technology Holdings are 5 of 6 investors who have invested in CellArtgen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process